Artificial Intelligence

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

With rare dual Google accreditations, Audiencerate offers a blueprint for privacy-first advertising in a world without third-party cookies.

Major e-commerce sales are fueling a tech race. How brands like EZVIZ use deep discounts to make advanced home security a reality for millions.

A new partnership aims to bypass slow, costly banking rails, using stablecoins to unlock faster, cheaper global transactions for businesses. Is this the future?

SSC's 37th dividend payment signals stability, but high payout ratios raise questions. Is management's growth-and-buyback strategy the right bet?

A new deal between Fushi Tech and tea giant PlayMade shows how AI and CRM are becoming critical tools for survival and growth in a competitive market.

One California firm is rewriting the rules of law with AI and global teams, achieving massive scale. Is this the future of legal services?

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

A new pact on quantum computing and AI safety aims to do more than innovate—it seeks to build a secure, equitable digital world for every citizen.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.